SCHEDULE: Versa Capital Group Discloses 10.8% Stake in Picard Medical

A group of entities and an individual associated with Versa Capital Group have reported beneficial ownership of 10.8% of Picard Medical, Inc.'s common stock.

Summary

• Sindex SSI Lending, LLC, Versa Capital Fund III, L.P., Versa FGP-III, L.P., Versa UGP-III, LLC, Versa Capital Group, LLC, and Gregory L. Segall (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons beneficially own an aggregate of 7,943,585 shares of common stock of Picard Medical, Inc.
• This ownership represents 10.8% of the issuer's common stock outstanding, calculated based on 73,701,176 shares issued and outstanding as of September 16, 2025.
• Each Reporting Person holds sole voting power and sole dispositive power over these 7,943,585 shares.
• The Reporting Persons certified that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a factual report of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant 10.8% stake by a group of entities and an individual could signal increased institutional interest. The explicit mention of potential activities solely in connection with a nomination under Rule 14a-11 suggests a potential for future engagement regarding board representation, which could influence investor perception and corporate governance.

Key Dates

Keywords

Picard Medical Inc, Sindex SSI Lending, Versa Capital Fund III, Versa FGP-III, Versa UGP-III, Versa Capital Group, Gregory L. Segall, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing, medical industry